BeiGene, Ltd. (BGNE) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Cambridge, MA, 미국. 현재 CEO는 John V. Oyler.
BGNE 을(를) 보유 IPO 날짜 2016-02-03, 10,600 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $20.21B.
BeiGene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for cancer treatment globally. The company's commercial portfolio includes approved drugs such as BRUKINSA for mantle cell lymphoma, Tislelizumab for Hodgkin's lymphoma, and several other therapies for hematologic and solid tumors, complemented by a robust pipeline of clinical-stage candidates targeting various cancer types through innovative mechanisms including BTK inhibitors, PD-1/PD-L1 antibodies, kinase inhibitors, and specialized immunotherapies. BeiGene maintains strategic partnerships with leading pharmaceutical companies including Amgen, Novartis, and Bristol Myers Squibb to strengthen its research and commercialization capabilities. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company operates a comprehensive oncology platform serving patients worldwide.
